Compare Heron Therapeutics Inc (HRTX) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs H2O America — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while H2O America trades at $58.71 (market cap $2.43B). The key difference: H2O America is far larger — about 35.7× Heron Therapeutics Inc's market cap, and H2O America pays a 3.03% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and H2O America for 40 Days on average.
| HRTX | HTO | |
|---|---|---|
Market Cap | $68.01M | $2.43B |
Volume | 1,891,941 | 593,883 |
Sector | Health | Utilities |
52-Week High | $1.49 | $65.43 |
52-Week Low | $0.27 | $44.44 |
Typical Hold Time | 35 Days | 40 Days |
Enterprise Value | $174.75M | $4.22B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
HTO trades at $57.98, down 0.34% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 12.91% net margin and 6.46% ROE, supported by recent acquisitions in Texas water utilities. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target, representing 15% upside potential from current levels.
The stock offers attractive dividend yield with recent $0.44 dividend declaration, but faces execution risks from acquisition integration and negative cash flow from investing activities. Technical indicators show mixed signals with oversold RSI readings conflicting with bearish moving averages, creating potential entry opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
